Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy

NCT02546102 is registered in ClinicalTrials.gov with Precision Life Sciences Group as lead sponsor.

NCT NCT02546102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02546102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Lead sponsor
Precision Life Sciences Group
Phase
Phase 3
Overall status
Suspended
Start date
December 31, 2024
Completion date
December 31, 2025
Enrollment
234 (estimated)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme